{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,1,5]],"date-time":"2024-01-05T19:23:59Z","timestamp":1704482639032},"reference-count":28,"publisher":"Elsevier BV","issue":"50","license":[{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1016\/j.vaccine.2016.10.019","type":"journal-article","created":{"date-parts":[[2016,11,2]],"date-time":"2016-11-02T15:00:25Z","timestamp":1478098825000},"page":"6381-6387","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Threshold cost-effectiveness analysis for a therapeutic vaccine against HPV-16\/18-positive cervical intraepithelial neoplasia in the Netherlands"],"prefix":"10.1016","volume":"34","author":[{"given":"Jos","family":"Luttjeboer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Didik","family":"Setiawan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qi","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toos","family":"CAHH Daemen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maarten J.","family":"Postma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2016.10.019_b0005","unstructured":"The Netherlands Cancer Registry. Dutch cancer figures. http:\/\/cijfersoverkanker.nl\/nkr\/index; [accessed 30.10.14]."},{"issue":"10","key":"10.1016\/j.vaccine.2016.10.019_b0010","doi-asserted-by":"crossref","first-page":";2349","DOI":"10.1002\/ijc.27485","article-title":"Human papillomavirus types in 115,789 HPV-positive women: a meta-analysis from cervical infection to cancer","volume":"15;131","author":"Guan","year":"2012","journal-title":"Int J Cancer"},{"key":"10.1016\/j.vaccine.2016.10.019_b0015","unstructured":"National Institute for Public Health and the Environment. Vaccinatiegraad Rijksvaccinatieprogramma Verslagjaar; 2014, www.rivm.nl; [accessed 29.06.15]."},{"key":"10.1016\/j.vaccine.2016.10.019_b0020","unstructured":"National Institute for Public Health and the Environment. Vernieuwing van het bevolkingsonderzoek. www.rivm.nl; [accessed 26.05.16]."},{"key":"10.1016\/j.vaccine.2016.10.019_b0025","unstructured":"National Institute for Public Health and the Environment. Bevolkingsonderzoek gaat veranderen. www.rivm.nl; [accessed 28.01.16]."},{"issue":"5","key":"10.1016\/j.vaccine.2016.10.019_b0030","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1002\/ijc.21955","article-title":"Overview of the European and North American studies on HPV testing in primary cervical cancer screening","volume":"119","author":"Cuzick","year":"2006","journal-title":"Int J Cancer"},{"issue":"3","key":"10.1016\/j.vaccine.2016.10.019_b0035","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1586\/14737159.2014.893829","article-title":"Arguments in favor of HPV testing for cervical screening and post-treatment CIN2+ monitoring","volume":"14","author":"Uijterwaal","year":"2014","journal-title":"Expert Rev Mol Diagn"},{"issue":"1","key":"10.1016\/j.vaccine.2016.10.019_b0040","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.ygyno.2013.11.001","article-title":"How distressing is referral to colposcopy in cervical cancer screening?: a prospective quality of life study","volume":"132","author":"Korfage","year":"2014","journal-title":"Gynecol Oncol"},{"issue":"5","key":"10.1016\/j.vaccine.2016.10.019_b0045","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.5306\/wjco.v5.i5.1002","article-title":"Immune therapy for human papillomaviruses-related cancers","volume":"5","author":"Rosales","year":"2014","journal-title":"World J Clin Oncol"},{"issue":"2","key":"10.1016\/j.vaccine.2016.10.019_b0050","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1097\/01.AOG.0000110246.93627.17","article-title":"ZYC101a for treatment of high-grade cervical intraepithelial neoplasia: a randomized controlled trial","volume":"103","author":"Garcia","year":"2004","journal-title":"Obstet Gynecol"},{"issue":"10008","key":"10.1016\/j.vaccine.2016.10.019_b0055","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1016\/S0140-6736(15)00239-1","article-title":"Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2\/3: a randomised, double blind, placebo-controlled phase 2b trial","volume":"386","author":"Trimble","year":"2015","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.vaccine.2016.10.019_b0060","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.ygyno.2007.05.038","article-title":"A phase II study of HSP-7 (SGN-00101) in women with high-grade cerivical intraepithelial neoplasia","volume":"106","author":"Roman","year":"2007","journal-title":"Gynecol Oncol"},{"issue":"2","key":"10.1016\/j.vaccine.2016.10.019_b0065","doi-asserted-by":"crossref","first-page":"169.e1","DOI":"10.1016\/j.ajog.2010.09.020","article-title":"Regression of high-grade cervical intraepithelial neoplasia with TG4001 targeted immunotherapy","volume":"204","author":"Brun","year":"2011","journal-title":"Am J Obstet Gynecol"},{"issue":"6","key":"10.1016\/j.vaccine.2016.10.019_b0070","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1038\/sj.cgt.7700937","article-title":"Regression of papilloma high-grade lesions (CIN 2 and CIN 3) is simulated by therapeutic vaccination with MVA E2 recombinant vaccine","volume":"13","author":"Garc\u00eda-Hern\u00e1ndez","year":"2006","journal-title":"Cancer Gene Ther"},{"key":"10.1016\/j.vaccine.2016.10.019_b0075","unstructured":"National Institute for Public Health and the Environment. Factsheet onderzoek baarmoederhalskanker, www.rivm.nl; [accessed 23.09.16]."},{"issue":"20","key":"10.1016\/j.vaccine.2016.10.019_b0080","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S0301-2115(01)00300-1","article-title":"Using a new HPV detection system in epidemiological research: change of views on cervical dyskaryosis?","volume":"98","author":"Reesink-Peters","year":"2001","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"1","key":"10.1016\/j.vaccine.2016.10.019_b0085","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1309\/AJCP03HUQYZMWATP","article-title":"Human papillomavirus (HPV) detection using in situ hybridization in histologic samples: correlations with cytologic changes and polymerase chain reaction HPV detection","volume":"136","author":"Kelesidis","year":"2011","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.vaccine.2016.10.019_b0090","unstructured":"van Ballegooijen M, Rebolj M, Essink-Bot ML, Meerding WJ, Berkers LM, Habbema JDF. De effecten en kosten van het bevolkingsonderzoek naar baarmoederhalskanker in Nederland na de herstructurering. <www.rivm.nl>; [accessed 20.11.14]."},{"issue":"6","key":"10.1016\/j.vaccine.2016.10.019_b0095","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1111\/j.1471-0528.2011.03228.x","article-title":"Cost-effectiveness of cervical cancer screening: cytology versus human papillomavirus DNA testing","volume":"119","author":"van Rosmalen","year":"2012","journal-title":"BJOG"},{"issue":"11","key":"10.1016\/j.vaccine.2016.10.019_b0100","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1111\/j.1471-0528.2007.01525.x","article-title":"Uterine artery embolisation or hysterectomy for the treatment of symptomatic uterine fibroids: a cost-utility analysis of the HOPEFUL study","volume":"114","author":"Wu","year":"2007","journal-title":"BJOG"},{"key":"10.1016\/j.vaccine.2016.10.019_b0105","unstructured":"The University Medical Center Groningen. UMCG Passantenprijzen 2015 Overige zorgproducten per 01\u201301-2015. <www.umcg.nl>; [accessed 07.02.15]."},{"key":"10.1016\/j.vaccine.2016.10.019_b0110","unstructured":"Statistics Netherlands. Consumentenprijzen; inflatie vanaf 1963, <http:\/\/statline.cbs.nl\/Statweb\/>; [accessed 21.11.14]."},{"key":"10.1016\/j.vaccine.2016.10.019_b0115","unstructured":"College voor zorgverzekeringen. Guidelines for pharmacoeconomic research, updated version. <www.cvz.nl>; [accessed 26.02.16]."},{"issue":"50","key":"10.1016\/j.vaccine.2016.10.019_b0120","doi-asserted-by":"crossref","first-page":"7327","DOI":"10.1016\/j.vaccine.2012.06.026","article-title":"Cost-effectiveness of pertussis booster vaccination in the Netherlands","volume":"30","author":"Rozenbaum","year":"2012","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2016.10.019_b0125","doi-asserted-by":"crossref","first-page":"149","DOI":"10.2165\/00019053-200018020-00005","article-title":"Differences in attitudes, knowledge and use of economic evaluations in decision-making in the Netherlands. The Dutch results from the EUROMET Project","volume":"18","author":"Zwart-van Rijkom","year":"2000","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.vaccine.2016.10.019_b0130","unstructured":"The Council for Health and Society. Zinnige en duurzame zorg. <www.rijksoverheid.nl>. [accessed 29.01.16]."},{"issue":"9","key":"10.1016\/j.vaccine.2016.10.019_b0135","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1111\/1471-0528.13398","article-title":"Is the increased risk of preterm birth following excision for cervical intraepithelial neoplasia restricted to the first birth post treatment?","volume":"122","author":"Castanon","year":"2015","journal-title":"BJOG"},{"issue":"232","key":"10.1016\/j.vaccine.2016.10.019_b0140","first-page":"1","article-title":"How many preterm births in England are due to excision of the cervical transformation zone? Nested case control study","volume":"15","author":"Wuntakal","year":"2015","journal-title":"BMC Pregnancy Childbirth"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X16309355?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X16309355?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,7]],"date-time":"2018-09-07T01:52:12Z","timestamp":1536285132000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X16309355"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12]]},"references-count":28,"journal-issue":{"issue":"50","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["S0264410X16309355"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2016.10.019","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2016,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Threshold cost-effectiveness analysis for a therapeutic vaccine against HPV-16\/18-positive cervical intraepithelial neoplasia in the Netherlands","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2016.10.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}